Slide 1: Quarter End Results, Period Ended June 30, 2024
Quarter End Results Period Ended June 30, 2024
Slide 2: Forward looking statements
Forward looking This presentation contains forward looking statements. The words “believe”, “expect”, development, uncertainties related to the outcome of clinical trials, slower than expected statement “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. ra
Slide 3: Strategic Partnerships, Collaborations, and Licensing Agreements
As part of Genmab’s First Half 2024 Results presentation, we will discuss Strategic several products developed in collaboration with strategic partners or that Partnerships, are the result of product or technology licenses with other companies. This slide is an acknowledgement of those relationships
Slide 4: Driving Towards Our 2030 Vision: Recent Company Events
Driving Towards Our 2030 Vision: Recent Company Events • Completion of ProfoundBio Acquisition • Acasunlimab (GEN1046, DuoBody-PD-L1x4-1BB) – Interim data from Phase 2 study in 2L NSCLC presented at • EPKINLY/TEPKINLY (epcoritamab) ASCO – U.S. FDA approval, relapsed or refractory FL – Genmab assumes
Slide 5: Significant Progress for Late-stage Clinical Programs: Acasunlimab
Significant Progress for Late-stage Clinical Programs - On Target for Advanced Development Acasunlimab • Very encouraging overall survival signal in Phase 2 2L+ NSCLC with Q6W combination schedule • Translational data to be presented at WCLC 2024 and other conferences • Phase 3 trial, on track for s
Slide 6: Rina-S: a Next-generation, Potential Best-in-class, FRα-targeted TOPO1 ADC
Rina-S: a Next-generation, Potential Best-in-class, FRα-targeted TOPO1 ADC Potential best-in-class, next-gen approach Possibility to address a broader patient population than first-generation FRα-targeted ADCs Differentiated Safety Profile avoiding ILD/pneumonitis and corneal toxicities Init
Slide 7: Significant Progress for Late-stage Clinical Programs: Rina-S
Significant Progress for Late-stage Clinical Programs - On Target for Advanced Development Rina-S • Phase 2 dose expansion ovarian cancer data to be presented at ESMO 2024 • Phase 3 trial in 2L+ PROC start anticipated before end of year © Genmab 2024 7 For Investor audience only. Not for public info
Slide 8: Select Royalty Medicines Portfolio Performance
Select Royalty Medicines Portfolio Performance Net sales (USD) YTD YoY DARZALEX • Patient share gains overall, driven by 1L $5,570M 19% • Final survival analysis of MAIA shows mOS of 7.5 years in 1L MM KESIMPTA $1,436M 64% • > 100,000 patients have now been treated worldwide TECVAYLI $903M 7% • Stro
Slide 9: Genmab Commercialized Medicines Performance
Genmab Commercialized Medicines Performance Net sales (USD) YTD* YoY** YTD YoY $ 121M - $60M 48% The CORE Therapy across B-cell Malignancies Clear answer in 2L+ cervical cancer • Asserting in-class leadership through competitive differentiation, • 11 consecutive quarters of demand growth, driven tar
Slide 10: H1 2024: Driving Towards Our 2030 Vision
H1 2024: Driving Towards Our 2030 Vision EPKINLY/TEPKINLY Regulatory Approvals & Launches, ProfoundBio Acquisition 42% increase in recurring revenues driving full year revenue guidance increase Focused Investment: expanding and accelerating our differentiated pipeline and our capabilities Team and c
Slide 11: ProfoundBio Acquisition: Enhancing Genmab's Long-term Growth Profile
ProfoundBio Acquisition: Enhancing Genmab’s Long-term Growth Profile Closing Date: May 21, 2024 Purchase Price: DKK 13.1B Acquisition, Integration & Operational Expenses Acquired Intangible Assets & Goodwill YTD 2024 Full Year 2024 Fair Value P&L Impact Actuals Forecast IPR&D Amortization commences
Slide 12: Royalties and Net Product Sales Drive 36% YoY Total Revenue Growth
Royalties and Net Product Sales & Collaboration Revenue* Drive 36% YoY Total Revenue Growth Revenue, DKK Millions +36% 9,545 42% Recurring Revenue growth from Royalties 912 and Net Product Sales & Collaboration Revenue 960 Higher DARZALEX Royalties from 19% YoY Net 7,003 Sales growth 938 179 DKK
Slide 13: Focused Investments in Pipeline and Capabilities
Focused Investments in Pipeline and Capabilities Operating Expenses, DKK Millions 6,729 252 Advancing Portfolio 173 Expanding mid/late stage development programs – 1,207 EPKINLY, Tivdak, acasunlimab, Rina-S, GEN1042 5,097 SG&A growth moderating which reflects our focus on driving efficiency Securi
Slide 14: Condensed Income Statement: Six Months Ended June 30
Condensed Income Statement: Six Months Ended June 30 2024 2023 2024 2023 DKKM Change USDM * Total Revenue 9,545 7,003 2,542 1,370 1,006 Royalties 7,673 5,886 1,787 1,101 845 Net Product Sales/Collaboration Revenue** 960 179 781 138 26 Milestone and Reimbursement 912 938 (26) 131 135 Gross Profit***
Slide 15: 2024 Guidance Update
2024 Guidance Update Revenue Growth Funds Additional Investment in Two Wholly Owned Portfolio Assets; Operating Profit Improves YoY Growth* Previous Previous Revenue growth of 28% vs previous 19%* driven DKK Billions Guidance Guidance Guidance Guidance by: DARZALEX royalties of ~DKK 13.3B to Reven
Slide 16: Genmab Delivers on Guidance Commitment
Genmab Delivers on Guidance Commitment Excluding classification of BioNTech partnership activities Operating Expenses, DKK Billions* 14.4 14.0 0.4 0.6 (0.3) 13.4 ProfoundBio operational spend driven mainly by 0.8 Rina-S investment 12.9 Genmab operational spend reduction driven by prioritization and
Slide 17: Summary
Summary Clear path to reach our 2030 Vision Growing recurring revenue streams and significant underlying profitability Focused and disciplined investment approach Significant growth opportunities supported by our capital allocation strategy © Genmab 2024 17 For Investor audience only. Not fo
Slide 18: 2024 Priorities
Further Advancing Our Differentiated 2024 Priorities: Product Pipeline Towards The Market Invest in Our People, Culture & Society Further scale organization aligned with differentiated Bring Our Own Medicines to Patients & Build World-class Differentiated antibody product portfolio Expand Our Market
Slide 19: Q&A, Upcoming Investor Events
Q&A Upcoming Investor Events • Virtual Handelsbanken Life Science Innovation Day, August 28, 2024 • Morgan Stanley Global Healthcare Conference, September 4-6, 2024 • BofA Global Healthcare conference, September 18-19, 2024 • JP Morgan European CEO Call Series, September 30, 2024 genmab.com © Genmab